Results from a prospective study by Santema and colleagues suggest that women with heart failure and reduced ejection fraction might need lower doses of standard heart failure drugs than men. However, this conclusion was formed on the basis of data from a small proportion of the population studied and might only be relevant to participants taking β-blockers.
This is a preview of subscription content, log in via an institution to check access.
References
Ponikowski, P. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. J. Heart Fail. 18, 891–975 (2016).
Hajahmadi, M. et al. Muscle wasting in young patients with dilated cardiomyopathy. J. Cachexia Sarcopenia Muscle 8, 542–248 (2017).
Santema, B. T. et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 394, 1254–1263 (2019).
Voors, A. A. et al. A systems biology study to tailored treatment in chronic heart failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur. J. Heart Fail. 18, 716–726 (2016).
Ouwerkerk, W. et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur. Heart J. 38, 1883–1890 (2017).
Lam, C. S. et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur. J. Heart Fail. 15, 928–936 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Coats, A.J.S. Drug dosing for heart failure: does sex or size matter?. Nat Rev Cardiol 16, 705–706 (2019). https://doi.org/10.1038/s41569-019-0298-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0298-7
- Springer Nature Limited